MedTrace Logo

The Impact of Vitamin D Supplementation in Hypertensive Vitamin D Deficient Patients.

NCT06645041 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-15

No results posted yet for this study

Summary

This study will assess the impact of Vitamin D supplementation on hypertensive patients with Vitamin D deficiency, it will also investigate the relationship between serum Vitamin D, irisin levels, blood pressure, and heart rate variability (HRV) in hypertensive and normotensive individuals.

It is hypothesized that a decrease in blood pressure and an increase in HRV will be noted in the hypertensive treatment group (subjects on supplemental vitamin D) in comparison to the hypertensive control group (placebo) upon vitamin D supplementation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Vitamin D (Cholecalciferol )

The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.

DIETARY_SUPPLEMENT

Placebo Capsule(s)

The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.

Sponsors & Collaborators

  • University of Sulaimani

    lead OTHER

Principal Investigators

  • Darya S. Abdulateef, Ph.D. · University of Sulaimani/College of Medicine/Branch of Medical Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-16
Primary Completion
2025-08-13
Completion
2025-08-13

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06645041 on ClinicalTrials.gov